https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/conference-coverage

The Latest

Risk of CVD or Type-2 Diabetes According to Change in BMI After Starting ART Img

Risk of CVD or Type-2 Diabetes According to Change in BMI After Starting ART

Initiation of antiretroviral therapy usually leads to increased weight and body mass index (BMI) that might be associated with an increased risk of cardiovascular disease and type-2 diabetes.

AIDS 2014: Mark Sulkowski on Hepatitis C Research (Video) Img

AIDS 2014: Mark Sulkowski on Hepatitis C Research (Video)

IFARA interviewed Mark Sulkowski, M.D., of Johns Hopkins University School of Medicine about new advances in hepatitis C screening and treatment.

COPD May Be Common and Underdiagnosed in People Living With HIV Img

COPD May Be Common and Underdiagnosed in People Living With HIV

Chronic obstructive pulmonary disease (COPD) was found in 9% of people living with HIV in a large French cohort -- and 77% of the cases were previously undiagnosed.

Hepatitis C Risk Among HIV-Negative Gay Men: Two Studies From ICAAC 2014 Img

Hepatitis C Risk Among HIV-Negative Gay Men: Two Studies From ICAAC 2014

Two studies examine the often overlooked hepatitis C (HCV) risk among HIV-negative men who have sex with men (MSM). While the incidence of HCV doesn’t appear to be great, screening is still uncommon and we may just be beginning to identify new cases....

Will There Ever Be a Hepatitis C Vaccine? Img

Will There Ever Be a Hepatitis C Vaccine?

Amidst the clamor and excitement of the ongoing hepatitis C (HCV) treatment renaissance, one word is rarely uttered: vaccine. But the hunt goes on, quietly -- and with great difficulty.

Hepatitis C Regimen, 3D, Cures 99% of Patients, With or Without Ribavirin Img

Hepatitis C Regimen, 3D, Cures 99% of Patients, With or Without Ribavirin

An oral, interferon-free combination of three drugs (ABT-450, ombitasvir and dasabuvir), administered with or without ribavirin, achieved a sustained virologic response 12 weeks post treatment (SVR12) in 99% of patients with chronic hepatitis C.

Short-Term Weight Gain Associated With Increase in CVD and Diabetes Post-ART in HIV Cohort Img

Short-Term Weight Gain Associated With Increase in CVD and Diabetes Post-ART in HIV Cohort

Data from a large cohort reveal much variability in mean weight gains after initiating ART, depending on the weight category before going on treatment.

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014 Img

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014

An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug Img

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug

HCV drugs are priced out of reach and out of control.

-- Michel Sidibé, UNAIDS

MELBOURNE, Australia -- Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead...

CROI 2014: Fair Pricing Coalition Seeks to Increase Access to HIV and HCV Treatment (Video) Img

CROI 2014: Fair Pricing Coalition Seeks to Increase Access to HIV and HCV Treatment (Video)

Lynda Dee of the Fair Pricing Coalition (FPC) spoke with coworkers Jeff Berry and Murray Penner, as well as David Evans of Project Inform, about access to HIV and hepatitis C (HCV) medications. FPC negotiates with pharmaceutical companies to make the...